Study identification

PURI

https://redirect.ema.europa.eu/resource/26344

EU PAS number

EUPAS13869

Study ID

26344

Official title and acronym

Retrospective Assessment of Treatment Patterns and Outcomes Associated with Palbociclib in Combination With Letrozole in Postmenopausal Women With HR+/HER2– Advanced Breast Cancer

DARWIN EU® study

No

Study countries

United States

Study description

To describe the patient and clinical characteristics, treatment patterns, and clinical outcomes of patients who received palbociclib plus letrozole for the treatment of HR+/ HER2- advanced breast cancer.

Study status

Finalised
Research institutions and networks

Institutions

Pfizer
First published:
01/02/2024
Institution
Multiple centres: 7 centres are involved in the study

Contact details

Debanjali Mitra

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Pfizer Inc
Study protocol
Initial protocol
English (498.32 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable